LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation ProgrammesBusiness Wire • 12/04/25
Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/04/25
Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous UrticariaZacks Investment Research • 11/25/25
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticariaGlobeNewsWire • 11/25/25
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing InvestorsNewsfile Corp • 11/18/25
Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetesGlobeNewsWire • 11/14/25
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority reviewGlobeNewsWire • 11/07/25
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient JourneyGlobeNewsWire • 10/28/25
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines DeclineZacks Investment Research • 10/24/25